glp-1 slidell for obesity GLP-1 Agonists For Obesity In Non-Diabetic Patients: Game Changer Or Overhyped? A Critical Analysis GlobalRPH GLP-1 and Inflammation: How These

The results of this study showed that GLP-1RA was superior to TZD in terms of reducing liver fat content and improving cardiometabolic risk parameters such as BMI and WC in overweight or obese patients with NAFLD or NASH

Bifidobacterium species are generally beneficial, producing short-chain fatty acids, supporting immune function, and helping with nutrient absorption

Chronic inflammation is a fundamental biological pathway involved in the development and progression of many cancers, said Dr Elizabeth Susan McDonald of the University of Pennsylvania

Tirzepatide demonstrated remarkable weight-reducing efficacy in randomized controlled trials such as SURMOUNT-1 and SURMOUNT-2, with mean body-weight reductions ranging from 15 to 22.5% (32, 33)